Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Silo Pharma (SILO) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Silo Pharma's Income towards Parent Company fell 1955.44% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 3669.93%. This contributed to the annual value of -$4.4 million for FY2024, which is 621160.92% down from last year.
  • Silo Pharma's Income towards Parent Company amounted to -$1.1 million in Q3 2025, which was down 1955.44% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Silo Pharma's Income towards Parent Company registered a high of -$1163.0 during Q1 2022, and its lowest value of -$1.8 million during Q1 2023.
  • Moreover, its 5-year median value for Income towards Parent Company was -$930296.5 (2024), whereas its average is -$783288.1.
  • As far as peak fluctuations go, Silo Pharma's Income towards Parent Company skyrocketed by 9826.33% in 2022, and later plummeted by 15577205.5% in 2023.
  • Over the past 5 years, Silo Pharma's Income towards Parent Company (Quarter) stood at -$25898.0 in 2021, then soared by 95.51% to -$1163.0 in 2022, then plummeted by 90319.26% to -$1.1 million in 2023, then plummeted by 64.57% to -$1.7 million in 2024, then soared by 35.84% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$1.2 million for Q2 2025, and -$1.0 million during Q1 2025.